A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741
This study is recruiting at 12 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumor
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- DualityBio Inc.
- Last updated on ClinicalTrials.gov
- April 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- University of California, Davis Comprehensive Cancer Center · Sacramento, CA
- UCLA Hematology/Oncology - Santa Monica · Santa Monica, CA
Florida · 4
- Sarah Cannon Research Institute at Florida Cancer Specialists · Orlando, FL
- BRCR global · Plantation, FL
- Florida Cancer Specialists · Sarasota, FL
- BRCR Medical Center Inc. · Tamarac, FL
Georgia · 1
- Research Site 111 · Atlanta, GA
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Michigan · 1
- Henry Ford Health System · Detroit, MI
Ohio · 1
- Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center · Cincinnati, OH
Tennessee · 1
- Tennessee Oncology, PLLC · Nashville, TN
Virginia · 1
- NEXT Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.